VIGL News and Press, Vigil Neuroscience Inc. From 09/11/23

- Complete Phase 1 data analysis demonstrated that VGL101 continued to have a favorable safety and tolerability profile and proof-of-target engagement in SAD/MAD cohorts up to 60 mg/kg - - On track to report 6-month interim data from IGNITE trial in Q4 2023 from first 6 patients who hav...

2023-09-08 17:51:57 ET More on Vigil Neuroscience Seeking Alpha’s Quant Rating on Vigil Neuroscience Historical earnings data for Vigil Neuroscience Financial information for Vigil Neuroscience For further details see: Vigil Neuroscience study for ...

2023-09-08 17:10:24 ET Gainers: Vigil Neuroscience ( NASDAQ: VIGL ) +7% . Tenaya Therapeutics ( TNYA ) +4% . CorMedix ( CRMD ) +4% . Xeris Biopharma  ( XERS ) +3% . Avidity Biosciences ( RNA ) +3% . Losers: The L...

- Announced VG-3927 as lead candidate to enter clinical development for potential treatment of Alzheimer’s Disease - - IND for VG-3927 now open; Phase 1 clinical trial in healthy volunteers allowed to proceed with partial clinical hold related to maximum exposure limit – ...

WATERTOWN, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of the management team will par...

2023-08-08 10:46:10 ET Vigil Neuroscience press release ( NASDAQ: VIGL ): Q2 GAAP EPS of -$0.52. Net Loss: Loss from operations for the second quarter ended June 30, 2023, were $20.2 million, compared to $17.0 million for the same period in 2022. Cash, cash equiva...

- Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in people living with ALSP expected in fourth quarter of 2023 - - Small molecule TREM2 agonist IND submission and initiation of Phase 1 clinical trial on track for fourth quarter of 2023 - - Appoints ...

WATERTOWN, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Christopher J. Silber, M.D. as...

WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of the management team will partici...

2023-05-10 13:50:48 ET Vigil Neuroscience press release ( NASDAQ: VIGL ): Q1 GAAP EPS of -$0.51 beats by $0.03 . Cash, cash equivalents, and marketable securities were $164.5 million as of March 31, 2023, compared to $186.6 million as of December 31, 2022. For fu...